Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Mechanism
GnRH agonist; sustained depot exposure can suppress the axis after initial stimulation.
Evidence and critical reading
Reported scientific and empirical uses
Fertility and reproduction
Indications depend on product/country; US TriptoDur addresses central precocious puberty.
Human evidence
A 24-week depot formulation is not equivalent to a short-acting peptide vial. Pediatric labeling must not become an adult “reset” protocol.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
A 24-week depot formulation is not equivalent to a short-acting peptide vial. Pediatric labeling must not become an adult “reset” protocol.
A 24-week depot formulation is not equivalent to a short-acting peptide vial. Pediatric labeling must not become an adult “reset” protocol.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: TriptoDur triptorelin depot is indicated for central precocious puberty from age 2. Other brands/countries have their own labels; do not transfer them to a catalog vial.
Adverse effects and unknowns
Initial hormonal worsening, hypersensitivity and mood/seizure effects are label issues; review age, context and product.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Triptorelin · 298 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07751133 · Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT04961996 · A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Registry status: Active, not recruitingLast update posted: October 15, 2026Query verification: October 16, 2026
NCT06763926 · Intranasal Nafarelin For Triggering Oocyte MaturationRegistry status: RecruitingLast update posted: October 15, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- REG-TRIPTODUR
DailyMed: TRIPTODUR triptorelin depot
October 16, 2026